Am J Transplant, Volume 19, Suppl 3 Archives - Page 6 of 214 - ATC Abstracts

2019 American Transplant Congress
A Safe Anti-A2 Titer for a Succesful A2 Incompatible Kidney Transplantation
G. Nair, M. Ajaimy, J. Graham, L. Liriano-Ward, A. Campbell, C. Pynadath, Y. Azzi, O. Andacoglu, S. Greenstein, M. Kinkhabwala, J. Rocca, E. Akalin
Montefiore Medical Center, Bronx, NY
*Purpose: The new kidney allocation system implemented in December 2014 allowed for use of A2/A2B donors to B recipients. However there is no mandate by…
2019 American Transplant Congress
Management of Anastomotic Biliary Strictures after Liver Transplant: Role of Covered Metal Stents
A. Watson¹, K. Haq¹, K. Khorfan², S. Singla¹, A. Yoshida³, D. Moonka¹
¹Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI, ²Internal Medicine, Henry Ford Hospital, Detroit, MI, ³Transplant Institute, Henry Ford Hospital, Detroit, MI
*Purpose: Biliary complications, including anastomotic biliary strictures (ABS), remain the most common cause of morbidity in liver transplant (LT) patients. Endoscopic therapy has become the…
2019 American Transplant Congress
Sub-Optimal Renal Recovery and Progressive Chronic Kidney Disease after Living Kidney Donation
Y. Kim¹, C. Jeong², H. Kim², J. Ha³, C. Ahn¹, Y. Kim¹, H. Lee¹
¹Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of, ²Department of Urology, Seoul National University Hospital, Seoul, Korea, Republic of, ³Department of Surgery, Seoul National University Hospital, Seoul, Korea, Republic of
*Purpose: Post-operative renal recovery after nephrectomy is a substantial problem to be addressed in living kidney donors. Herein, we explored factors associated with renal recovery…
2019 American Transplant Congress
Infectious Complications in Tocilizumab-Treated Kidney Transplant Recipients
S. Sethi, A. Peng, R. Najjar, A. Vo, S. Jordan, E. Huang
Cedars Sinai Medical Center, Los Angeles, CA
*Purpose: Tocilizumab blocks IL-6 signaling, inhibiting maturation of B cells to plasma cells and antibody production. We have used tocilizumab since 2012 to treat kidney…
2019 American Transplant Congress
Regulating T Cell Responses by Forced Transgenic Expression of Decay-Accelerating Factor
D. Heja¹, Z. He¹, S. A. Lira¹, F. Lin², D. Homann¹, P. S. Heeger¹
¹Icahn School of Medicine at Mount Sinai, New York, NY, ²Cleveland Clinic, Cleveland, OH
*Purpose: Decay-accelerating factor (DAF, CD55) is a cell surface expressed, glycophosphatidylinositol-(GPI)-anchored, complement regulator. Previous studies showed that during cognate T cell/antigen presenting cell (APC) interactions…
2019 American Transplant Congress
Factors Associated with Subclinical Cardiovascular Damage after Pediatric Liver Transplantation: A Longitudinal Observational Study
N. Memaran¹, I. Goldschmidt¹, B. Borchert¹, R. I. Sugianto¹, H. Wilke¹, R. Blöte¹, U. Baumann¹, E. Bauer¹, A. von Wick¹, N. Junge¹, C. Leiskau¹, E. D. Pfister¹, N. Richter², B. M. Schmidt³, A. Melk¹
¹Department of Pediatric Kidney, Liver, and Metabolic Diseases, Hannover Medical School, Hannover, Germany, ²Department of General, Visceral and Transplantation Surgery, Hannover Medical School, Hannover, Germany, ³Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany
*Purpose: Cardiovascular (CV) events account for 8-13% of deaths after liver transplantation (LT) in adulthood. While CV risk factors are present in children after LT…
2019 American Transplant Congress
Kidney Paired Donation Transplant Outcomes: Experiences from the First Ten Years of the National Kidney Registry
D. B. Leeser¹, A. G. Thomas², A. A. Shaffer², J. Veale³, A. B. Massie², M. Cooper⁴, S. Kapur⁵, S. Kapur⁵, S. Kapur⁵, N. Turgeon⁶, D. Segev², A. Waterman³, S. Flechner⁷
¹East Carolina Univ Sch of Med, Greenville, NC, ²Johns Hopkins, Baltimore, MD, ³UCLA, Los Angeles, CA, ⁴Georgetown, Washington, DC, ⁵Weill Cornell Medical School, New York, NY, ⁶Emory, Atlanta, GA, ⁷Cleveland Clinic, Cleveland, OH
*Purpose: In the United States (US), kidney paired donation (KPD) networks have facilitated an increasing proportion of KTs annually, but longer-term transplant outcomes and differences…
2019 American Transplant Congress
Epidemiology and Outcomes of BKV Nephropathy Management by Screening Policy in a Real-Life Setting
V. D. GARCIA¹, F. V. Raupp¹, G. MEINERZ¹, K. Piegas², E. KEITEL¹
¹Nephrology and Kidney and Pancreas Transplant Department, ISCMPA, Porto Alegre, Brazil, ²Pathology Department, ISCMPA, Porto Alegre, Brazil
*Purpose: To verify the frequency of BKVAN in a single center's clinical setting and evaluate the response to immunosuppressive adjustments through graft survival analysis.*Methods: Retrospective…
2019 American Transplant Congress
Assessing Pressure to Donate among Potential Living Kidney Donors
D. R. Helfer¹, J. Stanton², E. A. King¹, A. K. Eno¹, J. M. Ruck¹, A. A. Shaffer¹, A. G. Thomas¹, M. M. Waldram¹, A. M. Cameron¹, J. Kahn¹, L. Erby¹, M. L. Henderson¹, D. L. Segev¹, J. M. Garonzik Wang¹
¹Johns Hopkins University, Baltimore, MD, ²East Carolina University, Greenville, NC
*Purpose: In the setting of ongoing methods to increase living donation, including novel methods that harness the power of social media, it is imperative that…
2019 American Transplant Congress
Basiliximab versus T-cell Depleting Induction Therapy in Elderly Kidney Transplant Recipients
G. Vranic, H. Shah, B. Thomas, B. Javaid, J. Moore, M. Cooper, A. Gilbert
MedStar Georgetown Transplant Institute, Washington, DC
*Purpose: The ideal induction therapy for elderly kidney transplant recipients is not known. Given concerns about increased risk of infection and malignancy and perceived decreased…

« Previous Page
1
…
4
5
6
7
8
…
214
Next Page »